Ras inhibitors
AssigneeRevolution Medicines, Inc.
InventorsElena S. KOLTUN, James CREGG, Adrian L. GILL, James AGGEN, G. Leslie BURNETT, Jennifer PITZEN, Andreas BUCKL, John E. KNOX, Yang LIU
Life of this patent
Estimating the term…
Abstract
The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
Claims17
1-40. (canceled)
A method of treating cancer in a subject in need thereof, wherein the cancer comprises a K-Ras G12C mutation, the method comprising administering to the subject a therapeutically effective amount of a compound having the following structure:
- or a pharmaceutically acceptable salt thereof.
A method of treating non-small cell lung cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound having the following structure:
- or a pharmaceutically acceptable salt thereof.
A method of treating a Ras protein-related disorder in a subject in need thereof, wherein the Ras protein comprises a K-Ras G12C mutation, the method comprising administering to the subject a therapeutically effective amount of a compound having the following structure:
- or a pharmaceutically acceptable salt thereof.
A method of inhibiting a Ras protein in a cell, wherein the Ras protein comprises a K-Ras G12C mutation, the method comprising contacting the cell with an effective amount of a compound, or a pharmaceutically acceptable salt thereof, having the following structure:
Dependencies are inferred from the claim text.